Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. - Wikidata - wikimedia - TriplyDB

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

http://www.wikidata.org/entity/Q33429907

about

Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP.Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura.Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: A case report.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Mechanisms of Autoantibody-Induced Pathology.Durable antitumor responses to CD47 blockade require adaptive immune stimulation.Antibodies to watch in 2017 TMA secondary to SLE: rituximab improves overall but not renal survival.Monoclonal antibodies: technologies for early discovery and engineering.The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.Thrombotic microangiopathies: a general approach to diagnosis and management.Platelets and von Willebrand factor in atherogenesis.Diagnostic approach to microangiopathic hemolytic disorders.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A.Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.Pro: High dose of therapeutic plasma exchange-mind the gap!Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.Pathophysiology of thrombotic thrombocytopenic purpura.Recent advances in understanding and management of acquired thrombocytopenia.Nanobody Based Dual Specific CARs.Does Bernard-Soulier syndrome protect against thrombotic thrombocytopenic purpura?The role of von Willebrand factor in thrombotic microangiopathy.A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs.ADAMTS-13 and von Willebrand factor: a dynamic duo.The importance of clinical judgment for the diagnosis of thrombotic thrombocytopenic purpura.Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.[Clinical course and differential diagnosis of thrombotic microangiopathy].mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

P2860

Q28068448-C7C3A860-A720-4B24-A190-A63BA2870269 Q30276550-D8F41027-B7BB-4152-B806-3D270A458561 Q33431205-21CE41C4-8FD4-4ACE-B0C5-B4DF23FFD057 Q33435833-6362234B-F440-4BDD-A0E3-59048C4F07E8 Q33440745-DE2F6077-20AD-41D4-ACC4-0883349F6A86 Q33443111-EE892831-7D33-453C-B58E-98ECEF8211E6 Q33740580-F014D863-C216-4BC1-A632-40C266871186 Q36904867-B141C8CA-6B9D-45CD-A8D8-AED6B85A3702 Q37631319-538A9ECD-3C19-48E8-AC36-BC85940D6EB6 Q38601065-6CF71C7D-3A21-4E85-8890-D169389E6E80 Q38633596-7F4CAD87-92FB-47C4-8C04-CB2E39435487 Q38716432-230292AC-89A5-4568-874A-1550C0AB0359 Q38818496-05212C92-27FC-42AD-ADDF-2B255FA8F0CB Q38969861-5A8C32C4-8286-4818-8054-AE2C12A9F7D5 Q38984066-D866C46C-B685-4EE9-A136-499F78CBE637 Q39125083-1D02E81A-142E-4600-B9E3-2DB2FCEE894B Q39266338-A7C5EBEA-BBCE-4D87-9E3B-EF2457041129 Q42086661-7A0FC8EA-BAD5-4632-B1A3-EE91A84F0CEE Q45858905-4C7D982C-D289-45DB-9EE1-5B788DE138F1 Q45874207-A19776CA-FF7B-4898-BDCE-BAE5376F1302 Q47099672-9A73BFCB-ED2F-40E3-919A-548E485CD435 Q47134203-B1783D7A-D094-4406-A5BD-E2928860ACE6 Q47693300-27C92B07-46A7-4E1A-9145-2B1459FBD053 Q47741998-E63322FA-D25A-42F8-8649-67D31F880809 Q47912606-2F1B4A11-6C40-4358-9DEC-97138FBE25E5 Q47999124-2E82B7F1-8F4A-4410-90AE-AFE91DFAEECC Q48109292-5688BAB7-6967-4E54-BE27-10B39A247331 Q48132569-6D0D2BC7-7FFF-4F09-B753-20FCD70A976E Q48218018-E780C4FF-CB41-43C8-B591-6B369BD0545F Q48338971-5C3C38B2-5EBF-40AB-BD4E-4F165E60BB3E Q48509449-EB70F45E-41E1-4900-8836-C480C4538675 Q49832296-4FFCE019-164D-4F82-A223-75B1F8781B03 Q50135856-65EE3BAB-76D2-4477-8442-87A4E57137D7 Q50142987-7B67D97F-7547-499F-891F-3C1B3D5891D0 Q51202855-EF944C8E-9D51-4D9E-8993-8C3C63CAF8DA Q51306717-F022CFD5-B8E0-4489-B9A9-C97EEF0E0CB6 Q52759733-047A5459-2321-42ED-BC8B-B454442AB39F Q52995556-8F4C4C0F-6261-4705-8EDC-8A64EC77C771 Q55287154-EED0D984-164A-4CD4-AEBA-6D8DF89AE2EC Q56558457-E9942BF1-1C5D-4DC1-85DD-020A10A26A0E

P2860

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

http://www.wikidata.org/entity/Q33429907

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@ast

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@en

type

label

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@ast

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@en

prefLabel

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@ast

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@en

P1433

Q33429907-7D9158FE-F6ED-4EC7-8B28-2D35E52F3D55

P1476

Q33429907-E527CC72-10DB-4D45-B3B3-8A741FC4B6D5

P2093

Q33429907-2E35B461-AB60-4F65-B493-AE93DF9C2443

Q33429907-5FD9D96C-7457-45A2-AF92-80B142D16BB2

Q33429907-658E27B7-244E-4CF9-A005-EC4AE6CAABCE

Q33429907-6605B832-D11D-4CC9-8362-3C77A1F93AC0

Q33429907-6964BD1A-811E-472C-B25C-80BBAB946933

Q33429907-810E4765-24C8-4F9E-A12F-2F007A6E50AF

Q33429907-89618DE2-D46F-4D3A-B412-37C6EA0D1DCE

Q33429907-A3EC9B32-5F97-4E9F-A1EF-7D385DBF6201

Q33429907-AF271954-81C7-41BC-BE83-F574ADF79087

Q33429907-CD179AFB-4737-459A-AB34-B8685DC496A1

P304

Q33429907-0FB1A204-0DBA-4B6C-892A-A385719DE48C

P31

Q33429907-965321F4-39C5-452C-8EB4-791ECB6E301C

P356

Q33429907-F8C2900C-80AF-4DC9-BA32-EABFE98DF661

P407

Q33429907-4350C5D4-1C45-48CE-85BE-7CC36EC722CC

P433

Q33429907-C93D112A-959F-496D-97FD-FBAEE40DFA8B

P478

Q33429907-2F53E169-BAE7-407F-A1DE-D6A395E7FC64

P50

Q33429907-9088C145-8E75-44A2-B06B-59000BB8C9DC

Q33429907-DA8496F4-04B9-499D-951A-310C0993D93B

P577

Q33429907-D16131F6-608D-4214-9398-821CC9B49400

P698

Q33429907-446EC7E0-EA64-4EFE-A998-4AACCF82F629

P921

Q33429907-BB5CC23C-33CF-4305-86D7-55BFAA5A8226

P356

P1433

The New England Journal of Medicine

P1476

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

@en

P2093

Andrea Artoni

http://www.w3.org/2001/XMLSchema#string

Bernd Jilma

http://www.w3.org/2001/XMLSchema#string

Christian Duby

http://www.w3.org/2001/XMLSchema#string

Dominique Tersago

http://www.w3.org/2001/XMLSchema#string

Filip Callewaert

http://www.w3.org/2001/XMLSchema#string

Haifeng Wu

http://www.w3.org/2001/XMLSchema#string

Hans Ulrichts

http://www.w3.org/2001/XMLSchema#string

John-Paul Westwood

http://www.w3.org/2001/XMLSchema#string

Magnus Mansouri Taleghani

http://www.w3.org/2001/XMLSchema#string

Marie Scully

http://www.w3.org/2001/XMLSchema#string

P304

511-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1505533

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Johanna A Kremer Hovinga

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26863353

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia